Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose versus standard-dose adalimumab induction and maintenance for moderate to severe active Crohn's disease with mucosal ulceration
MOH_2017-02-09_000100Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of adalimumab in Crohn's disease, sponsored by AbbVie Inc. Started Aug 2014; status: active, not recruiting.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2017-02-09_000100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-02-09_000100.